AAOS: Driving Two Weeks Post Hip Replacement May Be OK

This article originally appeared here.
Share this content:
AAOS: Driving Two Weeks Post Hip Replacement May Be OK
AAOS: Driving Two Weeks Post Hip Replacement May Be OK

WEDNESDAY, March 25, 2015 (HealthDay News) -- Many people who've had hip replacement surgery might safely be able to drive as soon as two weeks after the procedure, a new small study finds. The findings were scheduled for presentation Tuesday at the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS), held from March 24 to 28 in Las Vegas. The study was also published online November 2014 in The Journal of Arthroplasty.

The new research included 38 people who underwent total hip replacement between 2013 and 2014. Their brake reaction time was tested before and after their procedure.

The results showed that 87 percent of the patients regained their presurgery brake reaction times within two weeks after surgery, and the other 13 percent reached that point within four weeks after surgery. There were no differences in terms of age, gender, or the use of assistance devices.

"We found that brake reaction time returned to baseline or better in the vast majority of patients undergoing contemporary total hip replacement by two weeks following surgery," study author and orthopedic surgeon Victor Hugo Hernandez, M.D., said in an AAOS news release. The "findings have allowed us to encourage patients to re-evaluate their driving ability as soon as two weeks after," total hip replacement, he added. However, Hernandez noted that the findings are based on this particular group of patients, and caution is needed in translating the results to the general population. Also, patients should never drive if they are still taking narcotic pain medications, he warned.

Abstract
Full Text (subscription or payment may be required)
Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FDA Panel Has Tie Vote on New Type ...

Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years

Frailty Could Increase Susceptibility for Dementia

Frailty Could Increase Susceptibility for Dementia

Authors say frailty should be considered in clinical care, management of Alzheimer dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »